Fabry disease
Advertisement
The INGLAXA study of an experimental gene therapy for cardiomyopathy in Fabry disease will resume after a hold was lifted.
A study found that renal progenitor cells may serve as an early biomarker for renal injury in Fabry disease.
Dr. Mohamed G. Atta discussed the importance of educating clinicians about Fabry disease.
Patients with Fabry disease face progressive decline in kidney function, as well as disorders of the nervous system and ...
Fabry disease, an X-linked rare disease, is characterized by deficient expression and activity of alpha-galactosidase A ...
Final results from the phase 3 BRIDGE clinical trial of pegunigalsidase alfa were presented at the 17th Annual ...
In a recent press release, the American Kidney Fund (AKF) announced an education and awareness campaign to increase ...
Chiesi Global Rare Diseases, a business unit of Chiesi Farmacuetici S. p.A., and Protalix Bio Therapeutics, Inc., ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.